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In Reply We are in agreement that adenosine-sensitive ven-
tricular tachycardia (VT) is apossibility.Various idiopathicVTs,
includingoutflow tract and fascicularVTs, can terminatewith
adenosine administration.1 Hence, termination of the tachy-
cardiawithadenosinealonewouldnotbediagnostic, andother
considerations, including the electrocardiogram and clinical
situation, should be taken into account to help make the di-
agnosis. Finally, if anatrial arrhythmiacontinuedwithoutven-
tricular conductiondue to atrioventricular block secondary to
adenosine use, this would be confirmation of supraventricu-
lar tachycardia.
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Angiotensin-Converting Enzyme Inhibitor
or Angiotensin Receptor Blocker Use
and Renal Outcomes: Prevalent User Designs
MayOverestimate Benefit
To the EditorThe recent studybyHsuet al1 regarding the reno-
protective effect of renin-angiotensin-aldosterone system
blockade in patients with predialysis advanced chronic kid-
neydisease,hypertension, andanemia is importantbutwebe-
lieve that the findings should be interpreted with caution.
According to the way that angiotensin-converting
enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB)
users were defined, people who had taken and then ceased
ACEI/ARB therapy prior to the first erythropoiesis-stim-
ulating agent (ESA) prescription would have been classified
as nonusers. For a proportion of these participants, ACEI/
ARB therapy may have been stopped for safety reasons, for
example, to attempt to delay dialysis treatment.2 Indeed,
25% of those defined as nonusers received a prescription for
ACEI/ARB in the 90 days prior to the first ESA prescription,
and many “nonusers” had clear indications for ACEI/ARB
therapy. This study design could create differential misclas-
sification where those defined as ACEI/ARB users were more
likely to have better kidney function or slower decline than
those defined as nonusers. A “new user” design including all
patients who initiate ACEI/ARB therapy rather than preva-
lent users may have led to less bias and provided a more bal-
anced comparison.3
To draw an analogy, in a study of car driving andmortality
riskamongpeople80yearsandolder, basedon thedesignused
byHsuetal,1wewouldclassifypeoplewhodonotcurrentlydrive
asnondrivers,evenif theyhadstoppeddrivingintheir70s.Many
of the peoplewho had stopped driving in their 70swould have
donesobecauseoffailinghealthandincreasedfrailty.Thisgroup
will, of course, be at high risk of dying. The studywill find that
driving is associated with marked survival benefits and might
leadus to advocate driving as awayof living longer. The reality
is that as people approach death they often decide it is time to
stopdriving.Abetterdesignwouldbe to start observingpeople
fromwhen they commenced driving.
Although the authors used a propensity score analysis to
try and ensure comparability between the groups, this can-
not compensate for unmeasured confounders, such as rate of
change of kidney function.4
Theauthorsconclude that“withholdingACEI/ARBtherapy
is unwarranted andmay hasten the onset of ESRD [end-stage
renal disease].”1(p353)Webelieve that the findings of this study
are interestingbut shouldnot provide false reassurance about
the effectiveness and safety of ACEI/ARB use in advanced
chronic kidney disease.
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In ReplyWeappreciate thecommentsofTomlinsonandSmeeth
concerning that thedifferentialmisclassificationwould tend to
bias our results toward favoring angiotensin-converting en-
zyme inhibitor or angiotensin receptor blocker (ACEI/ARB) use
inpatientswithpredialysisadvancedchronickidneydisease,hy-
pertension, and anemia. We performed additional analyses to
address the question raised in the letter. However, their specu-
lation is not evidenced by the further analysis fromour cohort.
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To minimize the possibility of misclassification of those
whohad taken and then, for safety reasons, ceasedACEI/ARB
therapyprior to the firsterythropoiesis-stimulatingagent (ESA)
prescription as nonusers, we redefined the nonusers (the ref-
erent group) as thosewho have not ever been treatedwith an
ACEI/ARB up to 3 months and 6 months before commencing
ESA therapy, respectively. Our data showed that the adjusted
hazard ratios (95% CIs) of chronic dialysis in ACEI/ARB users
were0.94 (0.91-0.97) and0.95 (0.92-0.98), respectively, andof
dialysis or death, 0.94 (0.91-0.96) and0.95 (0.92-0.98), respec-
tively. Similar results could also be observed in themultivari-
ablemodels further adjusted for thepropensity score. The se-
rial sensitivity analyses suggestourpreviouslypublisheddata1
that thehazard ratioof long-termdialysis ordeath for theACEI
or ARB users was 0.94 comparedwith nonusers was an unbi-
ased estimate.
Weacknowledge the “newuser”design2 is a goodmethod
for pharmaco-epidemiological research. However, it may not
be applicable to our study. In fact, the number of newACEI or
ARBuserswhohadneverusedanACEIorARBat least6months
prior to the first ESA prescriptionwas only 1159 (8.2% of total
ACEIorARBusers1) inourcohort.Thesamplesizewastoosmall
to secure a sufficient statistical power for the study. Few pa-
tientswith advanced chronic kidney diseasewere also recog-
nized to improve their renal functionby stoppingACEI orARB
therapy in our study,1 and it has beenmentioned in the small-
scaleobservational studybyAhmedet al.3However, our study
and the study by Ahmed et al3 are not comparable and have
differences in case number (28 497 vs 52), median follow-up
period (7 vs 30 months) and study outcomes (70.7% dialysis
and 20.0% death vs 9.6% dialysis and 9.6% death). Obvi-
ously, the medical conditions in our cohort were much com-
plex, indicating the beneficial impact of stopping ACEI/ARB
therapy observed in the study by Ahmed et al3 is not general-
izable to our study population.
In conclusion,weare confident in thevalidityofour study,
andwe also believe the observational study using a represen-
tative national database is one of the most feasible study de-
signs for the predialysis hypertensive patientswith advanced
CKD.The implicationof our study is to reassure that the reno-
protective effect of ACEI/ARBuse still exists in predialysis pa-
tients with advanced chronic kidney disease and “withhold-
ing ACEI/ARB therapy is unwarranted” for patients with
advanced CKD unless indicated by clinical evidence.
Chih-Cheng Hsu, MD, DrPH
Jia-Sin Liu, MS
Der-Cherng Tarng, MD, PhD
Author Affiliations:Division of Geriatrics and Gerontology, Institute of
Population Health Sciences, National Health Research Institutes, Zhunan,
Taiwan (Hsu, Liu); Department of Health Services Administration, China Medical
University and Hospital, Taichung, Taiwan (Hsu); Division of Nephrology,
Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
(Tarng); Institutes of Physiology and Clinical Medicine, National Yang-Ming
University, Taipei, Taiwan (Tarng).
Corresponding Author:Der-Cherng Tarng, MD, PhD, Division of Nephrology,
Department of Medicine, Taipei Veterans General Hospital, 201, Section 2,
Shih-Pai Road, Taipei 11217, Taiwan (dctarng@vghtpe.gov.tw).
Conflict of Interest Disclosures:None reported.
1. Hsu TW, Liu JS, Hung SC, et al. Renoprotective effect of renin-angiotensin-
aldosterone system blockade in patients with predialysis advanced chronic
kidney disease, hypertension, and anemia. JAMA Intern Med. 2014;174(3):
347-354.
2. RayWA. Evaluating medication effects outside of clinical trials: new-user
designs. Am J Epidemiol. 2003;158(9):915-920.
3. Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping
inhibitors of the renin-angiotensin system in patients with advanced chronic
kidney disease.Nephrol Dial Transplant. 2010;25(12):3977-3982.
ImprovingMedication Adherence andHelping
PatientsMake Lifestyle Changes
To the Editor In the studybyCohenet al,1 the authors report no
improvement in cardiovascular risk factorswhen dietician or
nurse-led educationwasprovided topatients following acute
coronarysyndrome(ACS)comparedwithusualcare.Thisstudy
represents analternative approach to standardeducational in-
terventions that could be provided through clinic-based car-
diac rehabilitation (CR) following ACS.
Anothermajor factor to considerwhenmodifying CR ser-
vices ismedicationadherence, as improvements in thisbehav-
iormaypredict further successwith other,more complex life-
style changes.2 In general, an adequate focus on medication
adherence has only been achieved by more intense CR pro-
grams requiring a longer schedule of visits.2 The study by Co-
hen et al1 appeared to have a sufficient level of intensity and
patient contact such that a pharmacist could have been in-
cluded in order to assess and promotemedication adherence.
As reportedbyCohenet al,1 it appears thatmedication ad-
herence in the study was high; however, they did not report
the percentage of patients stopping all guideline-recom-
mended medications. Only percentages for individual medi-
cations are presented, and this is an unusual and inadequate
measurement for reporting medication adherence.3 Ho et al4
demonstrated that patientswho stopusing allmedications by
1month after discharge are 10%more likely to have died dur-
ingthe12monthsfollowingACS.Giventhe12-monthtimeframe
of the study by Cohen et al1 and themultiple visits required in
the intervention, we would have been interested to see more
emphasis placedonadditionalmeasuresofmedicationadher-
ence and interventions seeking to improve it. We are cur-
rently conducting a study investigating the impact on medi-
cation adherence from pharmacist home visits following ACS
to help address this issue.5
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